<DOC>
	<DOCNO>NCT00878553</DOCNO>
	<brief_summary>SKP-1041 new formulation market sleep agent call zaleplon . Zaleplon currently available Sonata well several generic formulation . Sonata generic induce sleep soon ingestion . SKP-1041 , however , formulation design become active 2-3 hour ingestion . It intend use people trouble fall sleep often awaken middle night . This trial determine best dose prevent awakening .</brief_summary>
	<brief_title>Study Sleep-maintenance Activity 3 Doses SKP-1041</brief_title>
	<detailed_description>Patients participate study approximately 44 56 day , include 14- 21-day Screening Period , 4 Treatment Periods follow washout period , final Follow-up Visit . Patients receive randomly assign study medication spend 2 night sleep laboratory , subsequently return home 4- 7-day washout period treatment period . The fourth final treatment period include third night site patient continue receive study medication first 2 night treatment period . Blood drawn patient pharmacokinetic analysis specific time interval . Patients undergo final safety assessment 2 5 day last dose study medication .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Zaleplon</mesh_term>
	<criteria>Primary insomnia characterize chronic difficulty maintain sleep History restless legs syndrome , sleep apnea , narcolepsy , parasomnias ; Any clinically relevant acute chronic disease could interfere patient 's safety trial tablet 's absorption ; Pregnancy ; History medication allergy ; Use medication might interfere study ; Recent travel across 3 time zone .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>insomnia</keyword>
	<keyword>middle night</keyword>
	<keyword>sleep maintenance</keyword>
</DOC>